Quality of Life of HIV-infected Patients Study
|
|
- Valentine Heath
- 6 years ago
- Views:
Transcription
1 Investigator Name: Quality of Life of HIV-infected Patients Study OptumInsight is seeking for additional investigators for a multicenter longitudinal observational study involving adult patients with HIV. The study is sponsored by Merck & Co., Inc. Investigator must be a MD, DO, FNP, or a PA and must be able to prescribe treatment and assess SAEs. Last patient first visit is scheduled for August 2013 and therefore, your site must complete all required start-up procedures and be activated by June 5 th, Please read the study summary and respond to the following questions via Fax: MerckHIV@optum.com If you have any questions, please contact us by phone at or by at MerckHIV@optum.com If you do not want to receive further faxes from OptumInsight, please let us know by calling or by faxing us at You must include the telephone number or numbers of the fax machines you want to exclude. We will honor your request within 30 days; our failure to do so is unlawful. Feasibility Questionnaire Page 1 of 9
2 Research Interest Questionnaire This multi-site longitudinal observational study will enroll adult patients diagnosed with Human Immunodeficiency Virus (HIV) during normal medical visits. The enrollment period is 6 months with an expected enrollment of at least 5 patients per investigator; however, sites will not be limited to this number. The primary objective of this study is to compare quality of life (QOL) among HIV patients initiating or switching antiretroviral therapies for the first time. The primary comparisons will be among patients initiating or switching to integrase inhibitor+2 NRTI regimens versus a) NNRTI+2 NRTI regimens and b) PI+2 NRTIs regimens. For this observational study, sites will be asked to complete an electronic case report form at the enrollment visit for each participant, and participants will be asked to complete a baseline and follow-up survey. First patient was enrolled in December 2012 and patient enrollment is scheduled to go through August Patient eligibility criteria include the following: Patient Inclusion Criteria Patient Exclusion Criteria Clinical diagnosis of HIV 18 years of age If treatment-experienced, switching from first-line antiretroviral therapy to NNRTI, PI or integrase inhibitor-containing regimens(s) for the first time at the enrollment visit Have signed an informed consent form indicating that they understand the purpose of the study, the required study procedures, and that they are willing to participate in the study, and Ability to complete questionnaire in English Currently pregnant Presence of currently active tuberculosis, Hepatitis B, and/or Hepatitis C, and receiving treatment for the condition(s) during the study period (e.g., at the time of the enrollment visit and/or during the follow-up period) Presence of currently active pneumonia or other signs of opportunistic infections at the time of the enrollment visit Currently participating in a clinical trial or other research study that may interfere with the results of this study The physician investigator will: 1) be required to complete or confirm completion of human subjects protection training; 2) identify and approach potentially eligible HIV patients during a regularly scheduled visit to initiate or switch antiretroviral medication(s); 3) maintain an enrollment log with basic information of eligible patients who decline study participation; 4) follow a standardized protocol-designated process to solicit patient interest in study participation; 5) provide enrolled patients with written study documentation that describes the goals of the study, data collection and informed consent process; 6) obtain informed consent from the patients prior to any study-related procedures being conducted; 7) facilitate self-administered patient surveys according to protocol; and 8) complete an Internet-based case report form. Feasibility Questionnaire Page 2 of 9
3 1. Are you interested in participating in this study? please review the Investigator Contact Information box below and complete pages 3-9. please mark reason(s) below in Question 2, provide a response to Investigator s consent on page 9, and fax this page back to us at If you are not interested in participating, please indicate your reason. Please select all that apply. 1 Too busy to participate 2 Inadequate staffing/support to conduct research 3 Not interested in conducting research 4 Lack of appropriate patient population 5 Budget/financial reasons 6 Other (specify): 7 Please remove me from your mailing list 3. Investigator Contact Information: Please correct any information that is incomplete or incorrect. Investigator Name Clinic Name Address (1) Address (2) City/State/Zip Medical License Number Phone Contact Name Completed by (Name) Fax: Contact Date Completed: Position: Feasibility Questionnaire Page 3 of 9
4 Part 1: Staff and Facilities 4. The above-named investigator is a: 1 Physician (MD/DO) 2 Nurse Practitioner 3 Physician Assistant 4 Other (please specify below): 5. What is the primary specialty classification or area in which the above-named investigator works? 1 Family/General Practice 2 General Internal Medicine 3 Infectious Disease Specialist 4 Other (please specify below): 6. What is the primary practice setting of the abovenamed investigator? 1 Private practice 2 Group practice, single specialty 3 Group practice, multi-specialty 4 Employed by or affiliated with academic/university setting 5 Other (please specify below): 7. Is the investigator affiliated with a Research Organization or Site Management Organization (SMO)? 8. How many years has the above-named investigator been in practice? 9. What types of research studies has the above-named investigator participated in? (Check all that apply.) If Yes, please provide name of the Organization: 3 Do not know Years 1 Phase I 2 Phase II-III 3 Phase IV 4 Randomized clinical trials 5 Outcomes research 6 Survey research 7 Observational research 8 Focus groups 9 No research experience Feasibility Questionnaire Page 4 of 9
5 10. In the past 3 years, how many total studies has the investigator participated in? 11. Does the investigator have research experience conducting studies involving patients with HIV? 12. Please complete the table for 2 of the most recent HIV studies investigator has participated in, if applicable. Please include both the stop & start dates of the study (or if they are currently ongoing). total number of studies Study 1: Dates of study Did you meet the study enrollment goals? 3 Not applicable Study 2: Dates of study Did you meet the study enrollment goals? 3 Not applicable 13. Is the investigator currently conducting competing studies that would hinder your center s ability to participate in this study? 14. Is there a study coordinator available at this site to assist with this study? Site Study Coordinator Information If yes, please list brief study description(s) & dates: 1 Full-time 2 Part-time Name Phone Fax Years of experience Feasibility Questionnaire Page 5 of 9
6 Site Contract Specialist Information Not applicable Same as Study Coordinator Name Phone Fax 15. Does the investigator utilize a central IRB, a local IRB, or both? 16. If the investigator must utilize a local IRB, how often does the IRB meet? 17. If the investigator utilizes a local IRB, what is the average timeline from IRB submission to IRB approval? 18. If the investigator utilizes a local IRB, does the IRB allow for expedited review of non-interventional studies like this one? 19. How long does the contracting process take at your site on average? Feasibility Questionnaire Page 6 of 9 1 Central IRB 2 Local IRB 3 Central and Local IRB 4 Do not know 1 Weekly 2 Bi-Weekly 3 Monthly 4 >Monthly 5 Not applicable (use only Central IRB) 6 Do not know 1 <1 week weeks weeks weeks 5 >6 weeks 6 Not applicable (use only a Central IRB) 7 Do not know 8 What are your suggestions to accelerate the IRB approval process? 3 Do not know 1 <2 weeks weeks weeks 4 >6 weeks 5 Do not know 6 What are your suggestions to accelerate the contracting process?
7 20. Does your site have experience in Electronic Data Capture/ Remote Data Entry for clinical studies and access to a computer with internet access for data entry? 21. Does your site have available space for patients to complete patient questionnaires? 22. How many patients with HIV does the investigator see per month at your institution? Part 2: Patient Population patients per month 23. Of the patients with HIV that the investigator sees each month at your institution, approximately what percent are a) Newly/initially diagnosed with HIV? b) Previously diagnosed with HIV? % newly/initially diagnosed patients % previously diagnosed patients 24. Please query your database to specifically answer this question. How many 18 year old treatment-naïve HIV patients were first prescribed an antiretroviral therapy by the investigator during the past 12 months? 25. Please query your database to specifically answer this question. How many 18 year old HIV patients currently on first-line antiretroviral therapy does the investigator have listed in his/her own practice in the last 12 months? 26. Please query your database to specifically answer this question. How many 18 year old treatment experienced HIV patients were switched from first-line antiretroviral therapy to another therapy by the investigator during the past 12 months? patients in past 12 months patients in past 12 months patients in past 12 months Feasibility Questionnaire Page 7 of 9
8 27. How many total patients with HIV who are initiating or switching therapy do you estimate your site can consent and enroll in 6 months (taking into consideration study eligibility criteria, competing trials, resource capabilities at your site, and patients willingness to participate)? 28. Please specify the languages spoken by your patients and percentage of patient population. estimated total number of patients who can be enrolled Of those patients: estimated total number of patients initiating therapies who can be enrolled estimated total number of patients switching therapies who can be enrolled 1 English 2 US Spanish 3 Other, please specify: 29. Based on the current study design, do you anticipate any specific challenges that may make patient enrollment difficult? Part 3: Physician Referral 30. Are you aware of any other physicians who may be interested in participating in this study? (see below) If yes, please provide the physician s name and contact information: Investigator Name Specialty Clinic Name Address City/State/Zip Fax Phone Primary Contact Name Feasibility Questionnaire Page 8 of 9
9 Investigator s Consent (To Be Completed Regardless of Your Response to Question 1 Above) By checking the box marked yes below, I unambiguously and expressly consent to: 1.) the processing (including the collection, use, disclosure and transfer) of my personal data which is submitted or confirmed by me to OptumInsight, pursuant to any current or future study, or otherwise, inside and outside of the country in which I live and the member states of the European Union; 2.) the inclusion of my personal data (i.e., contact details and professional information) in the OptumInsight Global Investigator Database; 3.) being contacted by mail, facsimile, or by electronic mail or other electronic means about possible participation in current and future studies; In each case, for the purposes of the possible participation in current or future research projects and studies and any other purpose set out in the OptumInsight Global Privacy Policy*. Yes No, I wish for all personal information about me (other than that which is expressly or impliedly permitted or required by local law to be retained) to be removed from the OptumInsight Global Investigator Database. I do not wish to be contacted in the future, and I consent to allow OptumInsight to retain a minimal amount of my personal information for the limited purpose of complying with my request not to be contacted. *Please fax in writing to request a copy of the OptumInsight Global Privacy Policy, to amend any details in respect to your personal data, or to request removal from the OptumInsight Global Investigator Database. Investigator Date Please submit your completed questionnaire to Fax: MerckHIV@optum.com Thank you for your time and interest. We look forward to working with you! Feasibility Questionnaire Page 9 of 9
UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM. A5272 Version 2.0, 5/19/11: Oral HPV Shedding and Oral Warts After Initiation of Antiretroviral Therapy
A5272 Version 2.0, 5/19/11: Oral HPV Shedding and Oral Warts After Initiation of Antiretroviral Therapy CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND RESEARCH SUBJECT HIPAA AUTHORIZATION Your contacts
More informationHIV MANAGEMENT PROGRAMME APPLICATION FORM
Private Private Bag X82081, Bag X82081, Rustenburg, Rustenburg, 0300 0300 Tel: Tel: (014) 590 5901700 1900 Fax: Fax: 086 (014) 577 0274 591 4570 www.platinumhealth.co.za www.platinumhealth.co.za ZZGPlatinumHealthClinicalMotivation@angloamerican.com
More informationNursing and Midwifery students only. Section 1: Information
Nursing and Midwifery students only. Section 1: Information Students enrolled in programs offered by our School are REQUIRED to provide evidence of their immunisation status for the diseases listed in
More information-VFC Providers Influenza Vaccine and Preparedness Survey: Oregon-
-VFC Providers Influenza Vaccine and Preparedness Survey: Oregon- Directions: Please fill out the below survey. Once completed please fax your responses back to 404-712-8345, Attn. Allison Chamberlain.
More informationVERBAL CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND HIPPA AUTHORIZATION
VERBAL CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND HIPPA AUTHORIZATION Study Title: Cytokine Production and Lymphoproliferation With and Without Co-inhibitory Signaling Blockade: An Assessment of Functional
More informationDear Parent or Guardian,
Dear Parent or Guardian, This summer may be a period of transition for you and your child. For a lot of our students it may even be the first time they are taking the lead in their personal care, including
More informationDrug Prior Authorization Form Alertec (modafinil)
This document contains both information and form fields. To read information, use the Down Arrow from a form field. Drug Prior Authorization Form The purpose of this form is to obtain information required
More informationUNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM
Gilead Sciences, Inc. GS-US-337-0115, 25-NOV-2013 A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Subjects
More informationSurvey questionnaire on STI. surveillance, care and prevention. in European countries SAMPLE APPENDIX
European Surveillance of Sexually Transmitted Infections Survey questionnaire on STI surveillance, care and prevention in European countries APPENDIX Detailed questionnaire on clinician and laboratory
More informationMedical gap arrangements - practitioner application
Medical gap arrangements - practitioner application For services provided in a licensed private hospital or day hospital facility (Private Hospital) only. Please complete this form to apply for participation
More informationGreetings to all of you who provide valuable and vital health, human and related services in our communities!
WIN 2-1-1..Get Connected. Get answers. November 22, 2016 Greetings to all of you who provide valuable and vital health, human and related services in our communities! We are writing because we need your
More informationProposed Data Collection Submitted for Public Comment and. AGENCY: Centers for Disease Control and Prevention (CDC),
This document is scheduled to be published in the Federal Register on 09/26/2017 and available online at https://federalregister.gov/d/2017-20511, and on FDsys.gov BILLING CODE 4163-18-P DEPARTMENT OF
More informationTRANSITION OF CARE APPLICATION
Dear Member: Thank you for enrolling in MedStar Medicare Choice. You may currently be receiving services from healthcare providers that are not part of the MedStar Medicare Choice Provider Network. An
More information-VFC Providers Influenza Vaccine and Preparedness Survey: Louisiana-
-VFC Providers Influenza Vaccine and Preparedness Survey: Louisiana- Directions: Please fill out the below survey. Once completed please fax your responses back to 404-712-8345, Attn. Allison Chamberlain.
More informationType of Review Requested:
Type of Review Requested: FOR OFFICE USE ONLY IRB Protocol # Exempt [Status (see RR 101)] Expedited Full Board For details regarding types of review, please see Levels of Review under FAQ at www.seu.edu/irb
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Trogarzo) Reference Number: CP.PHAR.378 Effective Date: 04.17.18 Last Review Date: 05.18 Line of Business: Commercial, HIM-Medical Benefit, Medicaid Coding Implications Revision Log See
More informationHIV Drug Resistance. Together, we can change the course of the HIV epidemic one woman at a time.
HIV Drug Resistance Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Is Resistance? HIV drugs are designed to keep the amount of HIV virus
More informationStrategic Peer-Enhanced Care and Treatment Retention Model (SPECTRuM) Initiative. Intervention Protocol #2
MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH BUREAU OF INFECTIOUS DISEASE AND LABORATORY SCIENCES HIV/AIDS AND STD SURVEILLANCE PROGRAM AND OFFICE OF HIV/AIDS Strategic Peer-Enhanced Care and Treatment Retention
More information8: Applicability
Chapter 14 New Jersey State Sanitary Code Immunization of Pupils in Schools (New Jersey Administrative Code Citation 8:57-4.1 to 8:57-4.20) (Readopted with amendments September 20, 2003. Effective Date:
More informationUNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM CONSENT TO PARTICIPATE IN A LONG TERM FOLLOW UP TO A RESEARCH STUDY AND RESEARCH SUBJECT HIPAA AUTHORIZATION
UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM CONSENT TO PARTICIPATE IN A LONG TERM FOLLOW UP TO A RESEARCH STUDY AND RESEARCH SUBJECT HIPAA AUTHORIZATION Protocol No. VRX496-USA-11-001-LTFU: Long-term Follow-up
More informationCOLUMBIA UNIVERSITY INSTITUTIONAL REVIEW BOARD GUIDANCE ON ELECTRONIC INFORMED CONSENT
COLUMBIA UNIVERSITY INSTITUTIONAL REVIEW BOARD GUIDANCE ON ELECTRONIC INFORMED CONSENT I. BACKGROUND Electronic consenting ( e-consenting ) is the use of electronic systems and processes, whether in person
More informationPDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Fri, 23 Nov 2018 06:48:34 GMT) CTRI Number Last Modified On 18/02/2015 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
More informationPRO 140. First self-administered antibody therapy for HIV in late-stage clinical development. March
PRO 140 First self-administered antibody therapy for HIV in late-stage clinical development March 2018 Forward-Looking Statements This presentation includes forward-looking statements and forward-looking
More informationPart I. Prior Authorization Criteria and Policy
Texas Vendor Drug Program Antiviral Agents for Hepatitis C Virus Initial Authorization Request (Medicaid) Part I. Prior Authorization Criteria and Policy March 2018-E I. Eligibility 1. Patient is enrolled
More informationINITIAL PRACTICE PERIOD FORMS
INITIAL PRACTICE PERIOD FORMS 5060-3080 Yonge Street, Box 71 Toronto, Ontario M4N 3N1 416-975-5347 1-800-993-9459 www.caslpo.com Revised: May 2017 TABLE OF CONTENTS 1 MENTORSHIP GUIDANCE CONTRACT 3 2 1
More information11. NATIONAL DAFNE CLINICAL AND RESEARCH DATABASE
11. NATIONAL DAFNE CLINICAL AND RESEARCH DATABASE The National DAFNE Clinical and Research database was set up as part of the DAFNE QA programme (refer to section 12) to facilitate Audit and was updated
More informationDrug Prior Authorization Form Opdivo (nivolumab)
This document contains both information and form fields. To read information, use the Down Arrow from a form field. Drug Prior Authorization Form The purpose of this form is to obtain information required
More informationIRB Review Points to Consider September 2016
POINTS TO CONSIDER Principal investigators 1. Does the principal investigator have the appropriate qualifications, experience, and facilities to ensure that all aspects of the project and follow-up will
More informationMC IRB Protocol No.:
APPLICATION FORM - INITIAL REVIEW INSTITUTIONAL REVIEW BOARD Room 117 Main Building 555 Broadway Dobbs Ferry NY 10522 Phone: 914-674-7814 / Fax: 914-674-7840 / mcirb@mercy.edu MC IRB Protocol No.: Date
More informationMEMORANDUM OF UNDERSTANDING
Introduction MEMORANDUM OF UNDERSTANDING THE REDWOOD EMPIRE FOOD BANK 3320 Industrial Drive Santa Rosa, CA 95403 (707) 523-7900, Fax (707) 523-7050 and XXX COMMUNITY HEALTH CENTER Address Address Phone,
More informationGENERAL INFORMATION. Adverse Event (AE) Definition (ICH GUIDELINES E6 FOR GCP 1.2):
Make copies of the blank SAE report form as needed. Retain originals with confirmation of all information faxed to DMID Pharmacovigilance Group Clinical Research Operations and Management Support (CROMS
More informationICAP Journal Club. Article. Study Summary
ICAP Journal Club ICAP s Journal Club is designed to inform ICAP staff and colleagues of the latest scientific literature by providing a succinct summary and critical analysis of important studies, and
More informationENROLMENT FORM. Title: First Name: Surname: Postal Address: Postcode: Emergency Contact: Relationship: Phone: What is your main fitness goal?
ENROLMENT FORM Personal Information Title: First Name: Surname: Date of Birth: Sex: Female Male Postal Address: Postcode: Phone: Home: Work: Mobile: Email: Preferred method of contact: Letter Phone Email
More informationAPPLICATION TO INVOLVE HUMAN SUBJECTS IN RESEARCH (Form IAUPRIRB-1)
INTER AMERICAN UNIVERSITY OF PUERTO RICO INSTITUTIONAL REVIEW BOARD APPLICATION TO INVOLVE HUMAN SUBJECTS IN RESEARCH (Form IAUPRIRB-1) TITLE*: PRINCIPAL INVESTIGATOR S NAME, TELEPHONE AND POSTAL ADDRESS*:
More informationCHAPTER 7 SECTION 24.1 PHASE I, PHASE II, AND PHASE III CANCER CLINICAL TRIALS TRICARE POLICY MANUAL M, AUGUST 1, 2002 MEDICINE
MEDICINE CHAPTER 7 SECTION 24.1 ISSUE DATE: AUTHORITY: 32 CFR 199.4(e)(26) I. DESCRIPTION The Department of Defense (DoD) Cancer Prevention and Treatment Clinical Trials Demonstration was conducted from
More informationABC/3TC/ZDV ABC PBO/3TC/ZDV
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationNew Hope Free Clinic
MISSION STATEMENT The mission of New Hope Free Clinic is to provide the utmost in competent, high quality, wellness oriented, culturally attuned basic primary Medical and Dental Services in a loving and
More informationAmerican Cancer Society National Cancer Information Center (NCIC)
American Cancer Society National Cancer Information Center (NCIC) The American Cancer Society s National Cancer Information Center (NCIC) is a nationwide cancer help line open 24 hours a day, 7 days a
More informationWHI - Volume 3, Form 6 - Final Eligibility Assessment (Ver. 4) Page 1. Completed by Clinical Center (CC) staff; 2-page form; key-entered at CC.
WHI - Volume 3, Form 6 - Final Eligibility Assessment (Ver. 4) Page 1 FORM: 6 - FINAL ELIGIBILITY ASSESSMENT Version: 4 - June 1, 1995 Description: When used: Purpose: Completed by Clinical Center (CC)
More informationNorthwestern University. Consent Form and HIPAA Authorization for Research
Northwestern University Consent Form and HIPAA Authorization for Research PROTOCOL TITLE: Yoga Versus Resistance Training in Parkinson s Disease: A Randomized, Controlled Pilot Study of Feasibility & Efficacy
More informationUNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM
White Blood Cell Collection by Leukapheresis in HIV-infected Individuals On Chemotherapy and Controls Not on Chemotherapy: A Study of HIV Reservoir Eradication CONSENT TO PARTICIPATE IN A RESEARCH STUDY
More informationINFORMATION FOR RESEARCHERS REQUESTING DATA FROM THE NHVPR
INFORMATION FOR RESEARCHERS REQUESTING DATA FROM THE NHVPR What is the NHVPR? The National Human Papillomavirus Vaccination Program Register (NHVPR) is the Australian register which records HPV vaccine
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Enfuvirtide (Fuzeon) Reference Number: CP.PHAR.41 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end
More informationTITLE: Obtaining Informed Consent of Non-English Speakers SOP #: CON-101 (formerly SM-507) Page: 1 of 7 Effective Date: 1/14/2016
SOP #: CON-101 (formerly SM-507) Page: 1 of 7 Effective Date: 1. POLICY STATEMENT: All informed consent information (initial or updates for new information) must be presented in a language that is understandable
More informationSection 5. Study Procedures
Section 5. Study Procedures 5. Introduction 5-1 5.1 Visit Locations... 5-1 5.2 Eligibility Determination SOP... 5-1 5.3 Screening Visit... 5-2 5.3.1 Screening and Enrollment Timeframe... 5-2 5.3.2 Screening
More informationIRB GRAND ROUNDS SOCIAL AND BEHAVIORAL RESEARCH: NEED TO KNOW
IRB GRAND ROUNDS SOCIAL AND BEHAVIORAL RESEARCH: NEED TO KNOW Vivienne Carrasco, MPH,CIP Senior IRB Regulatory Analyst, Social and Behavioral Sciences Human Subject Research Office University of Miami
More informationNew Haven/Fairfield Counties Ryan White Part A Program Oral Health Standard of Care
DENTAL/ORAL HEALTH I. DEFINITION OF SERVICE Support for Oral Health Services including diagnostic, preventive, and therapeutic dental care that is in compliance with state dental practice laws, includes
More informationUNIVERSITY OF CALIFORNIA, SAN FRANCISCO CONSENT TO PARTICIPATE IN A RESEARCH STUDY
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO CONSENT TO PARTICIPATE IN A RESEARCH STUDY Study Title: Assessment of Biochemical Pathways and Biomarker Discovery in Autism Spectrum Disorder This is a research
More informationMRC S RECOVERY COACH ACADEMY APPLICATION
MRC S RECOVERY COACH ACADEMY APPLICATION TRAINING DATES I AM APPLYING FOR: April 23-27, 2018 I AM APPLYING: MRC SCHOLARSHIP EMPLOYEE OF AN ORGANIZATION SELF-FUNDED Other (please specify) IF APPLYING WITH
More informationProposed Amendment of 10A NCAC 26E.0603 Requirements for Transmission of Data
Proposed Amendment of 10A NCAC 26E.0603 Requirements for Transmission of Data Agency: Contact: DHHS/ Mental Health, Developmental Disabilities, and Substance Abuse Services Amanda Reeder, Rule-Making Coordinator
More informationChapter 18 Section 2. EXPIRED - Department Of Defense (DoD) Cancer Prevention And Treatment Clinical Trials Demonstration
s And Pilot Projects Chapter 18 Section 2 EXPIRED - Department Of Defense (DoD) Cancer Prevention And Treatment Clinical Trials 1.0 PURPOSE The purpose of this demonstration is to improve TRICARE-eligible
More informationAbout this consent form
Protocol Title: Development of the smoking cessation app Smiling instead of Smoking Principal Investigator: Bettina B. Hoeppner, Ph.D. Site Principal Investigator: n/a Description of Subject Population:
More informationLIMITED ENGLISH PROFICIENCY (LEP) AND LANGUAGE ASSISTANCE PLAN POLICY
675 Massachusetts Avenue Cambridge, MA 02139 www.cambridge-housing.org TDD 800 545 1833 x112 LIMITED ENGLISH PROFICIENCY (LEP) AND LANGUAGE ASSISTANCE PLAN POLICY The following policy applies to the Leased
More informationIRB Approved: 09-Jan-2015 To: 08-Jan-2016
Developing Assays to Evaluate Immunologic Response to HIV and HIV Vaccines CONSENT FORM/HIPAA AUTHORIZATION FOR VENIPUNCTURE Investigators: Pablo Tebas, MD Phone Number: (215) 349-8092 Study Staff: Joseph
More informationQUESTIONS AND ANSWERS
CONTACTS: Clare Collins Lisa Rossi +1-412-641-7299 +1-412-641-8940 +1-412-770-8643 (mobile) +1-412-916-3315 (mobile) collcx@upmc.edu rossil@upmc.edu QUESTIONS AND ANSWERS MTN-016: HIV Prevention Agent
More informationDefinition of Standing Order
Pediatric Immunization Refresher Immunization Documentation Massachusetts Department of Public Health Theodora Wohler, RN MPH Regional Immunization Nurses Definition of Standing Order A standing order
More informationHSPC/IRB Description of Research Form (For research projects involving human participants)
HSPC/IRB Description of Research Form (For research projects involving human participants) This form is to be completed by the Principal Investigator (P.I.) of the research project being submitted to the
More informationEbola Prevention Vaccine Evaluation in Sierra Leone
Ebola Prevention Vaccine Evaluation in Sierra Leone Dr. SAS Kargbo Sierra Leone Ministry of Health and Sanitation Sierra Leone CDC Collaboration World Health Organization, Geneva 9 January 2015 Principal
More informationInvestigator Initiated Study Proposal Form
Please submit completed form to IISReview@KCI1.com Date Submitted Name & Title Institution Address Phone Number Email Address Principal Investigator / Institution YES NO Multi Center Study Acelity Product(s)
More informationStudent Immunisation Record Faculty of Medicine. Section 1: Information. Notes
Student Immunisation Record Faculty of Section 1: Information Students enrolled in programs offered by the Faculty of are REQUIRED to provide evidence of their immunisation status for the diseases listed
More informationThe Johns Hopkins Bloomberg School of Public Health
The Johns Hopkins Bloomberg School of Public Health CONSENT FORM A / NEW RESEARCH PROJECT Title of Research Project: A Randomized Trial of HAART in Acute/Early HIV Infection Version 3.0 Principal Investigator:
More informationOral Health Assessment Handbook
Oral Health Assessment Handbook County of San Diego Health & Human Services Agency Maternal, Child, and Family Health Services Child Health and Disability Prevention Program Dental Health Initiative-Share
More informationSafety Regulations and Procedures Occupational Health Bloodborne Pathogens Exposure Control Plan S80.10, updated, May Contains information for:
APPENDIX A Safety Regulations and Procedures Occupational Health Bloodborne Pathogens Exposure Control Plan S80.10, updated, May 2018 BLOODBORNE PATHOGEN EXPOSURE INCIDENT PACKET Contains information for:
More informationStarting HIV Treatment
Starting HIV Treatment August 21, 2018 Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime#thewellproject First Things First When you and your health care provider
More informationWELLPOINT RESPONDS TO ANCO s COMMENTS
WELLPOINT RESPONDS TO ANCO s COMMENTS Thank you again for taking the time to meet with us to learn about Anthem s Cancer Care Quality Program and the Wellpoint Cancer Treatment Pathways as well as your
More informationIRB Approval From: 3/8/2010 To: 10/28/2010
UNIVERSITY OF PENNSYLVANIA HEALTH SYSTEM Phase II Study to Assess the Safety and Immunogenicity of an Inactivated Swine-Origin H1N1 Influenza Vaccine in HIV-1 (Version 3.0, 16 FEB 2010) IRB Approval From:
More informationMolina Healthcare of Texas Hepatitis C Drugs (Medicaid)
Texas Standard Prior Authorization Form Addendum Molina Healthcare of Texas Hepatitis C Drugs (Medicaid) This fax machine is located in a secure location as required by HIPAA Regulations. Complete / Review
More informationLast Name First name Academic degrees. Professional titles and/or work position within your home institution
Date received stamp ETHICS AND RESEARCH APPLICATION FORM Kenyatta National Hospital/University of Nairobi KEMRI CENTERS ETHICS RESEARCH COMMITTEE Application Number Submit three copies of this form (including
More informationThe OUTBACK Trial. Specific CRF Completion Guidelines
The OUTBACK Trial A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone (ANZGOG 0902, GOG 0274,
More informationKeep Smiling. DeltaCare USA. We keep you smiling
Keep Smiling DeltaCare USA We keep you smiling FAQ+A Answers to frequently asked questions about your DeltaCare USA plan GETTING STARTED 1. How do I enroll in a DeltaCare USA plan? Simply complete the
More informationNIH NEW CLINICAL TRIAL REQUIREMENTS AND FORMS-E
NIH NEW CLINICAL TRIAL REQUIREMENTS AND FORMS-E HOW DOES THE NIH DEFINE CLINICAL TRIAL AND HOW DO I KNOW IF MY STUDY IS ONE? 01-18-18 A clinical trial is defined by the NIH as a research study in which
More informationPDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Wed, 27 Mar 2019 20:50:17 GMT) CTRI Number CTRI/2009/091/001039 [Registered on: 15/10/2010] - Last Modified On 11/06/2015 Post Graduate Thesis Type of Trial
More informationPrepublication Requirements
Issued Prepublication Requirements The Joint Commission has approved the following revisions for prepublication. While revised requirements are published in the semiannual updates to the print manuals
More informationMEMBERSHIP APPLICATION INSTRUCTIONS
American Dental Association California Dental Association Stanislaus Dental Society MEMBERSHIP APPLICATION INSTRUCTIONS 1. Answer every question completely. Explain items in detail on a separate sheet
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective:
GSK Medicine: abacavir (ABC)/dolutegravir (DTG)/lamivudine (3TC) Study Number: 201147 Title: A IIIb, randomized, open-label study of the safety, efficacy, and tolerability of switching to a fixed-dose
More information3. Does the patient meet ALL of the following requirements? Y N
Pharmacy Prior Authorization AETA BETTER HEALTH FLORIDA Procrit - Retacrit (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign
More informationOffice of Clinical Research Annual Report 2017 July 1, June 30, 2017
Office of Clinical Research Annual Report 2017 July 1, 2016- June 30, 2017 Table of Contents Title Page Number Mission Statement 1 Objective 1 Research Services 1 Research Highlights 2 Figure 1 Number
More informationThe Chinese University of Hong Kong. Survey and Behavioural Research Ethics
The Chinese University of Hong Kong Survey and Behavioural Research Ethics GUIDELINES FOR SURVEY AND BEHAVIOURAL RESEARCH ETHICS A. Scope Survey and behavioural research covers surveys as well as observation
More information19 TH JUDICIAL DUI COURT REFERRAL INFORMATION
19 TH JUDICIAL DUI COURT REFERRAL INFORMATION Please review the attached DUI Court contract and Release of Information. ******* You must sign and hand back to the court the Release of Information today.
More informationGuidance for Industry
Reprinted from FDA s website by Guidance for Industry Bar Code Label Requirements Questions and Answers (Question 12 Update) DRAFT GUIDANCE This guidance document is for comment purposes only. Submit comments
More informationCannabis for Medical Purposes
College of Physicians and Surgeons of British Columbia Cannabis for Medical Purposes Preamble This document is a standard of the Board of the College of Physicians and Surgeons of British Columbia. College
More informationResearch Compliance and Quality Assurance Program (RCQA): Audit Checklist Subject Specific
Protocol Title / Code: Sponsor: PI Name: Auditor Name: Audit Date(s): Subject #: Key Dates: Date participant was identified: Date of Initial Consent: Date of Optional Consent: Date of Re-consent(s): Date
More informationEnsure access to and compliance with treatment for low-income uninsured Virginia residents living with HIV/AIDS
Public Health/ CHSB Lilibeth Grandas x1211 Sharron Martin x1239 Program Purpose Program Information Ensure access to and compliance with treatment for low-income uninsured Virginia residents living with
More informationGuidance - IDE Early/Expanded Access for Devices
Guidance - IDE Early/Expanded Access for Devices An unapproved medical device may normally only be used on human subjects through an approved clinical study in which the subjects meet certain criteria
More informationThe Hepatitis C Action Plan for Scotland: Draft Guidelines for Hepatitis C Care Networks
The Hepatitis C Action Plan for Scotland: Draft Guidelines for Hepatitis C Care Networks Royal College of Physicians of Edinburgh Friday 12 October 2007 CONTENTS 1.0 ACCOUNTABILITY AND ORGANISATION 2.0
More informationLimited English Proficiency Plan
Limited English Proficiency Plan September 2017 Limited English Proficiency Policy The Town follows Executive Order 13166 in identifying and engaging Limited English Proficiency (LEP) populations to ensure
More informationOCNA PUBLIC RELATIONS SUBCOMMITTEE GUIDELINES
MISSION STATEMENT: OCNA PUBLIC RELATIONS SUBCOMMITTEE GUIDELINES Our mission is to carry a clear message to the public and Narcotics Anonymous members of what Narcotics Anonymous is, what we do and why
More information[LIMITED ENGLISH PROFICIENCY PLAN] Table of Contents
[LIMITED ENGLISH PROFICIENCY PLAN] December 2007 [LIMITED ENGLISH PROFICIENCY PLAN] Table of Contents Introduction. 3 Executive Order 13166. 3 Plan Summary. 3 Four Factor Analysis. 4-5 Limited English
More informationNYC AUTISM CHARTER SCHOOL BRONX School Year Application. Preference is given based upon the following criteria in the following order:
BRONX 2018-2019 School Year Application NYC Autism Charter School (NYCACS) operates two schools, NYCACS Bronx and NYCACS East Harlem. Each school will hold a lottery for students whose birthdate falls
More informationASSEMBLY COMMITTEE ON HUMAN SERVICES Blanca Rubio, Chair AB 2702 (McCarty) As Amended April 2, 2018
Page 1 Date of Hearing: April 24, 2018 SUBJECT: Trustline registry. ASSEMBLY COMMITTEE ON HUMAN SERVICES Blanca Rubio, Chair AB 2702 (McCarty) As Amended April 2, 2018 SUMMARY: Requires the Department
More information2010 Sharing Hope Program for men
2010 Sharing Hope Program for men Criteria and Application Made possible by participating sperm banks and fertility centers Program Overview Goal Cancer patients have little opportunity to save for the
More informationRequest for Special Authorization Enbrel
Certain prescription drugs call for a more detailed assessment to help ensure that they represent reasonable treatment. Special Authorization requires that you request approval from Great-West Life for
More informationResearch Consent Form Newton-Wellesley Hospital 2014 Washington Street Newton, MA 02462
Protocol Title: Principal Investigator: Description of Subject Population: Protocol Version: Consent Form Revision Date: ABOUT THIS CONSENT FORM STUDY CONTACTS
More informationIRB EXPEDITED REVIEW
IRB EXPEDITED REVIEW Research activities that (1) present no more than minimal risk* to human research participants, and (2) involve only procedures listed in one or more of the following categories may
More informationNational Cancer Information Center
National Cancer Information Center The American Cancer Society s National Cancer Information Center (NCIC) is a nationwide cancer help line open 24 hours a day, 7 days a week. The NCIC has trained Cancer
More informationRequest for Proposal. PA ACT 139 Naloxone Purchase
Request for Proposal PA ACT 139 Naloxone Purchase Proposals due by February 6, 2014, 4:00PM 3905 N. Front Street Harrisburg, PA 17110-1536 Phone (717) 236-1059 Table of Contents PA ACT 139... I NALOXONE
More informationSection VII: HIV/AIDS & STD. MPR 1 Provide and/or refer clients for HIV and STD screening and treatment, regardless of client ability to pay.
All Minimum Program Requirements (MPRs) and Indicators listed below are required for the agency to meet in order to pass the HIV/AIDS and STD section of the Accreditation Review. Sources of authority:
More informationName: Address: City: State: Zip: Phone: Cell: Work: Fax: Best time to call: Reference (Name and or phone):
TRAINING APPLICATION 2018 No trainings are currently planned but you are welcome to complete and return this application form. You will be contacted when a training is scheduled. Please complete the application
More information